Data Show Promise of Pirtobrutinib in Treatment of CLL, SLL
July 6th 2023Pirtobrutinib is a non–covalent (reversible) BTK inhibitor, demonstrating a 73.3% overall response rate with a median follow-up of 19.4 months among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More
Public Health Matters - Discussing Charitable Pharmacies
July 6th 2023On this episode of Public Health Matters, Christina Madison speaks with Lydia Bailey, PharmD, BCACP, pharmacy operations manager for St. Vincent de Paul Charitable Pharmacy in Cincinnati, Ohio about what charitable pharmacies are.
Listen